{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:42:51Z","timestamp":1791517371467,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_170249"],"award-info":[{"award-number":["320030_170249"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40262-017-0513-9","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T06:38:16Z","timestamp":1487054296000},"page":"1219-1230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects"],"prefix":"10.1007","volume":"56","author":[{"given":"Patrick C.","family":"Dolder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Steuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina M.","family":"Rentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"issue":"4","key":"513_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295\u2013314.","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"513_CR2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355.","journal-title":"Pharmacol Rev"},{"key":"513_CR3","doi-asserted-by":"crossref","unstructured":"Krebs TS, Johansen PO. Over 30 million psychedelic users in the United States. F1000Res. 2013;2:98.","DOI":"10.12688\/f1000research.2-98.v1"},{"issue":"3","key":"513_CR4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1503\/cmaj.1150082","volume":"188","author":"WJ Davenport","year":"2016","unstructured":"Davenport WJ. Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache. CMAJ. 2016;188(3):217.","journal-title":"CMAJ"},{"issue":"1","key":"513_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29(1):57\u201368.","journal-title":"J Psychopharmacol."},{"issue":"7","key":"513_CR6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513\u201320.","journal-title":"J Nerv Ment Dis."},{"issue":"4","key":"513_CR7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/2045125314527985","volume":"4","author":"D Baumeister","year":"2014","unstructured":"Baumeister D, Barnes G, Giaroli G, Tracy D. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol. 2014;4(4):156\u201369.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"7","key":"513_CR8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994\u20131002.","journal-title":"J Psychopharmacol."},{"issue":"6192","key":"513_CR9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1126\/science.345.6192.18","volume":"345","author":"K Kupferschmidt","year":"2014","unstructured":"Kupferschmidt K. High hopes. Science. 2014;345(6192):18\u201323.","journal-title":"Science"},{"key":"513_CR10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1017\/S0033291715002901","volume":"46","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Kaelen M, Bolstridge M, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:1379\u201390.","journal-title":"Psychol Med"},{"issue":"8","key":"513_CR11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi E, Roseman L, Kaelen M, et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol. 2016;26(8):1043\u201350.","journal-title":"Curr Biol"},{"key":"513_CR12","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.euroneuro.2016.03.018","volume":"26","author":"M Kaelen","year":"2016","unstructured":"Kaelen M, Roseman L, Kahan J, et al. LSD modulates music-induced imagery via changes in parahippocampal connectivity. Eur Neuropsychopharmacol. 2016;26:1099\u2013109.","journal-title":"Eur Neuropsychopharmacol"},{"key":"513_CR13","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci. 2016;113:4853\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"513_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuropsychologia.2016.04.005","volume":"88","author":"DB Terhune","year":"2016","unstructured":"Terhune DB, Luke DP, Kaelen M, et al. A placebo-controlled investigation of synaesthesia-like experiences under LSD. Neuropsychologia. 2016;88:28\u201334.","journal-title":"Neuropsychologia"},{"issue":"4","key":"513_CR15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0269881116628430","volume":"30","author":"J Speth","year":"2016","unstructured":"Speth J, Speth C, Kaelen M, et al. Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. J Psychopharmacol. 2016;30(4):344\u201353.","journal-title":"J Psychopharmacol."},{"key":"513_CR16","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/hbm.23224","volume":"37","author":"L Roseman","year":"2016","unstructured":"Roseman L, Sereno MI, Leech R, et al. LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. Hum Brain Mapp. 2016;37:3031\u201340.","journal-title":"Hum Brain Mapp"},{"key":"513_CR17","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/hbm.23234","volume":"37","author":"AV Lebedev","year":"2016","unstructured":"Lebedev AV, Kaelen M, Lovden M, et al. LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp. 2016;37:3203\u201313.","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"513_CR18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","volume":"232","author":"RL Carhart-Harris","year":"2015","unstructured":"Carhart-Harris RL, Kaelen M, Whalley MG, et al. LSD enhances suggestibility in healthy volunteers. Psychopharmacology. 2015;232(4):785\u201394.","journal-title":"Psychopharmacology"},{"issue":"19","key":"513_CR19","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","volume":"232","author":"M Kaelen","year":"2015","unstructured":"Kaelen M, Barrett FS, Roseman L, et al. LSD enhances the emotional response to music. Psychopharmacology. 2015;232(19):3607\u201314.","journal-title":"Psychopharmacology"},{"key":"513_CR20","doi-asserted-by":"crossref","first-page":"12374","DOI":"10.1111\/jne.12374","volume":"28","author":"P Strajhar","year":"2016","unstructured":"Strajhar P, Schmid Y, Liakoni E, et al. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol. 2016;28:12374.","journal-title":"J Neuroendocrinol"},{"key":"513_CR21","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, Mueller F, et al. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638\u201346.","journal-title":"Neuropsychopharmacology."},{"issue":"8","key":"513_CR22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Enzler F, Gasser P, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78(8):544\u201353.","journal-title":"Biol Psychiatry"},{"key":"513_CR23","doi-asserted-by":"crossref","unstructured":"Dolder PC, Schmid Y, Haschke M, et al. Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol. 2015;19:pii: pyv072.","DOI":"10.1093\/ijnp\/pyv072"},{"key":"513_CR24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt196455611","volume":"5","author":"GK Aghajanian","year":"1964","unstructured":"Aghajanian GK, Bing OH. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin Pharmacol Ther. 1964;5:611\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"513_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0009-8981(72)90159-3","volume":"36","author":"DG Upshall","year":"1972","unstructured":"Upshall DG, Wailling DG. The determination of LSD in human plasma following oral administration. Clin Chim Acta. 1972;36(1):67\u201373.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"513_CR26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jat\/26.4.193","volume":"26","author":"KL Klette","year":"2002","unstructured":"Klette KL, Horn CK, Stout PR, Anderson CJ. LC-MS analysis of human urine specimens for 2-oxo-3-hydroxy LSD: method validation for potential interferants and stability study of 2-oxo-3-hydroxy LSD under various storage conditions. J Anal Toxicol. 2002;26(4):193\u2013200.","journal-title":"J Anal Toxicol"},{"issue":"3","key":"513_CR27","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00414-012-0796-1","volume":"127","author":"R Martin","year":"2013","unstructured":"Martin R, Schurenkamp J, Gasse A, et al. Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS\/MS. Int J Legal Med. 2013;127(3):593\u2013601.","journal-title":"Int J Legal Med"},{"key":"513_CR28","doi-asserted-by":"publisher","unstructured":"Steuer AE, Poetzsch M, Stock L, et al. Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS\/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Test Anal. 2016. doi: 10.1002\/dta.2042 (Epub ahead of print).","DOI":"10.1002\/dta.2042"},{"key":"513_CR29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00216-014-8388-1","volume":"407","author":"PC Dolder","year":"2015","unstructured":"Dolder PC, Liechti ME, Rentsch KM. Development and validation of a rapid turboflow LC-MS\/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases. Anal Bioanal Chem. 2015;407:1577\u201384.","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"513_CR30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpt1979253358","volume":"25","author":"LB Sheiner","year":"1979","unstructured":"Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979;25(3):358\u201371.","journal-title":"Clin Pharmacol Ther"},{"key":"513_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4453-0","author":"ME Liechti","year":"2016","unstructured":"Liechti ME, Dolder PC, Schmid Y. Alterations in conciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology (Berl). 2016;. doi: 10.1007\/s00213-016-4453-0 (Epub ahead of print).","journal-title":"Psychopharmacology (Berl)."},{"issue":"3","key":"513_CR32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1749-6632.1957.tb40742.x","volume":"66","author":"L Sokoloff","year":"1957","unstructured":"Sokoloff L, Perlin S, Kornetsky C, Kety SS. The effects of D-lysergic acid diethylamide on cerebral circulation and over-all metabolism. Ann NY Acad Sci. 1957;66(3):468\u201377.","journal-title":"Ann NY Acad Sci."},{"issue":"5","key":"513_CR33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cpt196895635","volume":"9","author":"JG Wagner","year":"1968","unstructured":"Wagner JG, Aghajanian GK, Bing OH. Correlation of performance test scores with \u201ctissue concentration\u201d of lysergic acid diethylamide in human subjects. Clin Pharmacol Ther. 1968;9(5):635\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"513_CR34","volume-title":"Studies in routes of administration and counteracting drugs: lysergic acid diethylmide and mescaline in experimental psychosis","author":"PH Hoch","year":"1956","unstructured":"Hoch PH. Studies in routes of administration and counteracting drugs: lysergic acid diethylmide and mescaline in experimental psychosis. New York: Grune and Stratton; 1956."},{"key":"513_CR35","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26:1327\u201337.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"513_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fphar.2016.00211","volume":"14","author":"AR Gallimore","year":"2016","unstructured":"Gallimore AR, Strassman RJ. A model for the application of target-controlled intravenous infusion for prolonged immersive DMT psychedelic experience. Front Pharmacol. 2016;14(7):211. doi: 10.3389\/fphar.2016.00211 .","journal-title":"Front Pharmacol."},{"issue":"2","key":"513_CR37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N, N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51(2):98\u2013108.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"513_CR38","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/0269881110367445","volume":"25","author":"RL Carhart-Harris","year":"2011","unstructured":"Carhart-Harris RL, Williams TM, Sessa B, et al. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. J Psychopharmacol. 2011;25(11):1562\u20137.","journal-title":"J Psychopharmacol."},{"issue":"2","key":"513_CR39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans. Clin Pharmacol Ther. 2011;90(2):246\u201355.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"513_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2190\/5X0N-TWKJ-GGY6-T10N","volume":"12","author":"C Dyke Van","year":"1982","unstructured":"Van Dyke C, Ungerer J, Jatlow P, et al. Intranasal cocaine: dose relationships of psychological effects and plasma levels. Int J Psychiatry Med. 1982;12(1):1\u201313.","journal-title":"Int J Psychiatry Med"},{"issue":"5","key":"513_CR41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archneurpsyc.1956.02330290012002","volume":"76","author":"RE Belleville","year":"1956","unstructured":"Belleville RE, Fraser HF, Isbell H, et al. Studies on lysergic acid diethylamide (LSD-25): I. Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA. Arch Neurol Psychiatry. 1956;76(5):468\u201378.","journal-title":"Arch Neurol Psychiatry."},{"key":"513_CR42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00213-012-2761-6","volume":"224","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Liechti ME. Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology. 2012;224:363\u201376.","journal-title":"Psychopharmacology"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0513-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0513-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T13:15:00Z","timestamp":1568812500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0513-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0513-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]}}}